Time-lapse mapping of cortical changes in schizophrenia with different treatments

Paul M. Thompson, George Bartzokis, Kiralee M. Hayashi, Andrea D. Klunder, Po H. Lu, Nancy Edwards, Michael S. Hong, Michael Yu, Jennifer A. Geaga, Arthur W. Toga, Cecil Charles, Diana O. Perkins, Joseph McEvoy, Robert M. Hamer, Mauricio Tohen, Gary D. Tollefson, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Using time-lapse maps, we visualized the dynamics of schizophrenia progression, revealing spreading cortical changes that depend on the type of antipsychotic treatment. Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24.2 ± 5.1 SD years) randomized to haloperidol (HAL) (n = 15) or olanzapine (OLZ) treatment (n = 21), imaged at baseline, 3, 6, and 12 months (144 scans). Based on surface-based cortical models and point-by-point measures of gray matter volume, we generated time-lapse maps for each treatment. Disease trajectories differed for atypical versus typical neuroleptic drugs. A rapidly advancing parietal-to-frontal deficit trajectory, in HAL-treated patients, mirrored normal cortical maturation but greatly intensified. The disease trajectory advanced even after symptom normalization, involving the frontal cortex within 12 months with typical drug treatment. Areas with fastest tissue loss shifted anteriorly in the first year of psychosis. This trajectory was not seen with OLZ. Whether this association reflects either reduced neurotoxicity or neuroprotection cannot be addressed with neuroimaging; changes may relate to glial rather than neural components. These maps revise current models of schizophrenia progression; due to power limitations, the findings require confirmation in a sample large enough to model group × time interactions.

Original languageEnglish (US)
Pages (from-to)1107-1123
Number of pages17
JournalCerebral Cortex
Volume19
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

olanzapine
Schizophrenia
Haloperidol
Antipsychotic Agents
Frontal Lobe
Therapeutics
Neuroimaging
Neuroglia
Psychotic Disorders
Disease Progression
Magnetic Resonance Imaging
Brain
Pharmaceutical Preparations

Keywords

  • Cortex
  • Development
  • Imaging
  • Neurotoxicity
  • Schizophrenia

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Thompson, P. M., Bartzokis, G., Hayashi, K. M., Klunder, A. D., Lu, P. H., Edwards, N., ... Lieberman, J. A. (2009). Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex, 19(5), 1107-1123. https://doi.org/10.1093/cercor/bhn152

Time-lapse mapping of cortical changes in schizophrenia with different treatments. / Thompson, Paul M.; Bartzokis, George; Hayashi, Kiralee M.; Klunder, Andrea D.; Lu, Po H.; Edwards, Nancy; Hong, Michael S.; Yu, Michael; Geaga, Jennifer A.; Toga, Arthur W.; Charles, Cecil; Perkins, Diana O.; McEvoy, Joseph; Hamer, Robert M.; Tohen, Mauricio; Tollefson, Gary D.; Lieberman, Jeffrey A.

In: Cerebral Cortex, Vol. 19, No. 5, 01.05.2009, p. 1107-1123.

Research output: Contribution to journalArticle

Thompson, PM, Bartzokis, G, Hayashi, KM, Klunder, AD, Lu, PH, Edwards, N, Hong, MS, Yu, M, Geaga, JA, Toga, AW, Charles, C, Perkins, DO, McEvoy, J, Hamer, RM, Tohen, M, Tollefson, GD & Lieberman, JA 2009, 'Time-lapse mapping of cortical changes in schizophrenia with different treatments', Cerebral Cortex, vol. 19, no. 5, pp. 1107-1123. https://doi.org/10.1093/cercor/bhn152
Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex. 2009 May 1;19(5):1107-1123. https://doi.org/10.1093/cercor/bhn152
Thompson, Paul M. ; Bartzokis, George ; Hayashi, Kiralee M. ; Klunder, Andrea D. ; Lu, Po H. ; Edwards, Nancy ; Hong, Michael S. ; Yu, Michael ; Geaga, Jennifer A. ; Toga, Arthur W. ; Charles, Cecil ; Perkins, Diana O. ; McEvoy, Joseph ; Hamer, Robert M. ; Tohen, Mauricio ; Tollefson, Gary D. ; Lieberman, Jeffrey A. / Time-lapse mapping of cortical changes in schizophrenia with different treatments. In: Cerebral Cortex. 2009 ; Vol. 19, No. 5. pp. 1107-1123.
@article{517d5ce3c00245df972d5c2b8f2f2c67,
title = "Time-lapse mapping of cortical changes in schizophrenia with different treatments",
abstract = "Using time-lapse maps, we visualized the dynamics of schizophrenia progression, revealing spreading cortical changes that depend on the type of antipsychotic treatment. Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24.2 ± 5.1 SD years) randomized to haloperidol (HAL) (n = 15) or olanzapine (OLZ) treatment (n = 21), imaged at baseline, 3, 6, and 12 months (144 scans). Based on surface-based cortical models and point-by-point measures of gray matter volume, we generated time-lapse maps for each treatment. Disease trajectories differed for atypical versus typical neuroleptic drugs. A rapidly advancing parietal-to-frontal deficit trajectory, in HAL-treated patients, mirrored normal cortical maturation but greatly intensified. The disease trajectory advanced even after symptom normalization, involving the frontal cortex within 12 months with typical drug treatment. Areas with fastest tissue loss shifted anteriorly in the first year of psychosis. This trajectory was not seen with OLZ. Whether this association reflects either reduced neurotoxicity or neuroprotection cannot be addressed with neuroimaging; changes may relate to glial rather than neural components. These maps revise current models of schizophrenia progression; due to power limitations, the findings require confirmation in a sample large enough to model group × time interactions.",
keywords = "Cortex, Development, Imaging, Neurotoxicity, Schizophrenia",
author = "Thompson, {Paul M.} and George Bartzokis and Hayashi, {Kiralee M.} and Klunder, {Andrea D.} and Lu, {Po H.} and Nancy Edwards and Hong, {Michael S.} and Michael Yu and Geaga, {Jennifer A.} and Toga, {Arthur W.} and Cecil Charles and Perkins, {Diana O.} and Joseph McEvoy and Hamer, {Robert M.} and Mauricio Tohen and Tollefson, {Gary D.} and Lieberman, {Jeffrey A.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1093/cercor/bhn152",
language = "English (US)",
volume = "19",
pages = "1107--1123",
journal = "Cerebral Cortex",
issn = "1047-3211",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Time-lapse mapping of cortical changes in schizophrenia with different treatments

AU - Thompson, Paul M.

AU - Bartzokis, George

AU - Hayashi, Kiralee M.

AU - Klunder, Andrea D.

AU - Lu, Po H.

AU - Edwards, Nancy

AU - Hong, Michael S.

AU - Yu, Michael

AU - Geaga, Jennifer A.

AU - Toga, Arthur W.

AU - Charles, Cecil

AU - Perkins, Diana O.

AU - McEvoy, Joseph

AU - Hamer, Robert M.

AU - Tohen, Mauricio

AU - Tollefson, Gary D.

AU - Lieberman, Jeffrey A.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Using time-lapse maps, we visualized the dynamics of schizophrenia progression, revealing spreading cortical changes that depend on the type of antipsychotic treatment. Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24.2 ± 5.1 SD years) randomized to haloperidol (HAL) (n = 15) or olanzapine (OLZ) treatment (n = 21), imaged at baseline, 3, 6, and 12 months (144 scans). Based on surface-based cortical models and point-by-point measures of gray matter volume, we generated time-lapse maps for each treatment. Disease trajectories differed for atypical versus typical neuroleptic drugs. A rapidly advancing parietal-to-frontal deficit trajectory, in HAL-treated patients, mirrored normal cortical maturation but greatly intensified. The disease trajectory advanced even after symptom normalization, involving the frontal cortex within 12 months with typical drug treatment. Areas with fastest tissue loss shifted anteriorly in the first year of psychosis. This trajectory was not seen with OLZ. Whether this association reflects either reduced neurotoxicity or neuroprotection cannot be addressed with neuroimaging; changes may relate to glial rather than neural components. These maps revise current models of schizophrenia progression; due to power limitations, the findings require confirmation in a sample large enough to model group × time interactions.

AB - Using time-lapse maps, we visualized the dynamics of schizophrenia progression, revealing spreading cortical changes that depend on the type of antipsychotic treatment. Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24.2 ± 5.1 SD years) randomized to haloperidol (HAL) (n = 15) or olanzapine (OLZ) treatment (n = 21), imaged at baseline, 3, 6, and 12 months (144 scans). Based on surface-based cortical models and point-by-point measures of gray matter volume, we generated time-lapse maps for each treatment. Disease trajectories differed for atypical versus typical neuroleptic drugs. A rapidly advancing parietal-to-frontal deficit trajectory, in HAL-treated patients, mirrored normal cortical maturation but greatly intensified. The disease trajectory advanced even after symptom normalization, involving the frontal cortex within 12 months with typical drug treatment. Areas with fastest tissue loss shifted anteriorly in the first year of psychosis. This trajectory was not seen with OLZ. Whether this association reflects either reduced neurotoxicity or neuroprotection cannot be addressed with neuroimaging; changes may relate to glial rather than neural components. These maps revise current models of schizophrenia progression; due to power limitations, the findings require confirmation in a sample large enough to model group × time interactions.

KW - Cortex

KW - Development

KW - Imaging

KW - Neurotoxicity

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=67649224058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649224058&partnerID=8YFLogxK

U2 - 10.1093/cercor/bhn152

DO - 10.1093/cercor/bhn152

M3 - Article

C2 - 18842668

AN - SCOPUS:67649224058

VL - 19

SP - 1107

EP - 1123

JO - Cerebral Cortex

JF - Cerebral Cortex

SN - 1047-3211

IS - 5

ER -